Aquaporin 1 promotes sensitivity of anthracycline chemotherapy in breast cancer by inhibiting β-catenin degradation to enhance TopoIIα activity

Anthracyclines are a class of conventional and commonly used frontline chemotherapy drugs to treat breast cancer. However, the anthracycline-based regimens can only reduce breast cancer mortality by 20–30%. Furthermore, there is no appropriate biomarker for predicting responses to this kind of chemo...

Full description

Saved in:

Bibliographic Details
Published in:	Cell death and differentiation Vol. 28; no. 1; pp. 382 - 400
Main Authors:	Chong, Wei, Zhang, Huikun, Guo, Zhifang, Yang, Limin, Shao, Ying, Liu, Xiaoli, Zhao, Yawen, Wang, Zhe, Zhang, Ming, Guo, Caixia, Fu, Li, Ma, Yongjie, Gu, Feng
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-01-2021 Nature Publishing Group
Subjects:	13 13/51 13/95 14/19 38/61 38/77 38/91 45/23 64/60 692/53/2423 692/699/67/1857 Animals Anthracycline Anthracyclines - therapeutic use Antibiotics, Antineoplastic - therapeutic use Apoptosis Aquaporin 1 Aquaporin 1 - metabolism beta Catenin - metabolism Biochemistry Biomedical and Life Sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cell Biology Cell Cycle Analysis Chemotherapy Cytoplasm Female Glycogen Glycogen synthase kinase 3 Humans Kinases Life Sciences Mice Mice, Inbred BALB C Mice, Nude Nuclear transport Patients Prognosis Stem Cells Xenograft Model Antitumor Assays β-Catenin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!